Logo image of TNGX

TANGO THERAPEUTICS INC (TNGX) Stock Fundamental Analysis

USA - NASDAQ:TNGX - US87583X1090 - Common Stock

7.97 USD
+0.17 (+2.18%)
Last: 9/25/2025, 5:33:14 PM
7.97 USD
0 (0%)
After Hours: 9/25/2025, 5:33:14 PM
Fundamental Rating

3

TNGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 538 industry peers in the Biotechnology industry. The financial health of TNGX is average, but there are quite some concerns on its profitability. TNGX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TNGX had negative earnings in the past year.
In the past year TNGX has reported a negative cash flow from operations.
In the past 5 years TNGX always reported negative net income.
In the past 5 years TNGX always reported negative operating cash flow.
TNGX Yearly Net Income VS EBIT VS OCF VS FCFTNGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

The Return On Assets of TNGX (-61.19%) is comparable to the rest of the industry.
TNGX's Return On Equity of -107.86% is in line compared to the rest of the industry. TNGX outperforms 43.68% of its industry peers.
Industry RankSector Rank
ROA -61.19%
ROE -107.86%
ROIC N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
TNGX Yearly ROA, ROE, ROICTNGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

TNGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNGX Yearly Profit, Operating, Gross MarginsTNGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

More info and screens

6

2. Health

2.1 Basic Checks

TNGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TNGX has more shares outstanding
TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TNGX Yearly Shares OutstandingTNGX Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TNGX Yearly Total Debt VS Total AssetsTNGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of 0.32, we must say that TNGX is in the distress zone and has some risk of bankruptcy.
TNGX's Altman-Z score of 0.32 is fine compared to the rest of the industry. TNGX outperforms 60.78% of its industry peers.
TNGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACC9.87%
TNGX Yearly LT Debt VS Equity VS FCFTNGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 4.75 indicates that TNGX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.75, TNGX is in line with its industry, outperforming 52.23% of the companies in the same industry.
A Quick Ratio of 4.75 indicates that TNGX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.75, TNGX is in line with its industry, outperforming 53.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.75
Quick Ratio 4.75
TNGX Yearly Current Assets VS Current LiabilitesTNGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

TNGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.67%.
Looking at the last year, TNGX shows a very negative growth in Revenue. The Revenue has decreased by -42.84% in the last year.
TNGX shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.34% yearly.
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-45.83%
Revenue 1Y (TTM)-42.84%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%-83.99%

3.2 Future

The Earnings Per Share is expected to grow by 10.05% on average over the next years. This is quite good.
The Revenue is expected to grow by 40.69% on average over the next years. This is a very strong growth
EPS Next Y1.61%
EPS Next 2Y-8.28%
EPS Next 3Y-7.53%
EPS Next 5Y10.05%
Revenue Next Year8.58%
Revenue Next 2Y-38.75%
Revenue Next 3Y-22.25%
Revenue Next 5Y40.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TNGX Yearly Revenue VS EstimatesTNGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
TNGX Yearly EPS VS EstimatesTNGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TNGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TNGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNGX Price Earnings VS Forward Price EarningsTNGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNGX Per share dataTNGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

TNGX's earnings are expected to decrease with -7.53% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-8.28%
EPS Next 3Y-7.53%

More info and screens

0

5. Dividend

5.1 Amount

TNGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TANGO THERAPEUTICS INC

NASDAQ:TNGX (9/25/2025, 5:33:14 PM)

After market: 7.97 0 (0%)

7.97

+0.17 (+2.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)11-04 2025-11-04/bmo
Inst Owners96.83%
Inst Owner Change16.47%
Ins Owners1.57%
Ins Owner Change-6.31%
Market Cap886.74M
Analysts86.67
Price Target11.09 (39.15%)
Short Float %24.28%
Short Ratio15.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.26%
Min EPS beat(2)-0.84%
Max EPS beat(2)1.36%
EPS beat(4)2
Avg EPS beat(4)6.79%
Min EPS beat(4)-1.28%
Max EPS beat(4)27.91%
EPS beat(8)4
Avg EPS beat(8)8.87%
EPS beat(12)7
Avg EPS beat(12)10.28%
EPS beat(16)10
Avg EPS beat(16)9.26%
Revenue beat(2)0
Avg Revenue beat(2)-37.17%
Min Revenue beat(2)-53.3%
Max Revenue beat(2)-21.03%
Revenue beat(4)1
Avg Revenue beat(4)-19.16%
Min Revenue beat(4)-53.3%
Max Revenue beat(4)45.73%
Revenue beat(8)3
Avg Revenue beat(8)11.17%
Revenue beat(12)5
Avg Revenue beat(12)16.64%
Revenue beat(16)6
Avg Revenue beat(16)11.78%
PT rev (1m)8.75%
PT rev (3m)8.75%
EPS NQ rev (1m)59.6%
EPS NQ rev (3m)84.41%
EPS NY rev (1m)0%
EPS NY rev (3m)16.72%
Revenue NQ rev (1m)58.59%
Revenue NQ rev (3m)470.7%
Revenue NY rev (1m)13.01%
Revenue NY rev (3m)70.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 36.5
P/FCF N/A
P/OCF N/A
P/B 6.57
P/tB 6.57
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-1.42
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.22
BVpS1.21
TBVpS1.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.19%
ROE -107.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.42%
ROA(5y)-20.6%
ROE(3y)-49.57%
ROE(5y)-33.14%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.56%
Cap/Sales 3.74%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.75
Quick Ratio 4.75
Altman-Z 0.32
F-Score1
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)190.33%
Cap/Depr(5y)N/A
Cap/Sales(3y)12.3%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-45.83%
EPS Next Y1.61%
EPS Next 2Y-8.28%
EPS Next 3Y-7.53%
EPS Next 5Y10.05%
Revenue 1Y (TTM)-42.84%
Revenue growth 3Y4.34%
Revenue growth 5YN/A
Sales Q2Q%-83.99%
Revenue Next Year8.58%
Revenue Next 2Y-38.75%
Revenue Next 3Y-22.25%
Revenue Next 5Y40.69%
EBIT growth 1Y-18.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.03%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-38.65%
OCF growth 3YN/A
OCF growth 5YN/A